Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deltacortil is a brand name for prednisolone, a synthetic glucocorticoid corticosteroid marketed by Lucky Core Industries (LCI), formerly known as ICI Pakistan. As a small molecule glucocorticoid receptor agonist, it mimics the effects of endogenous cortisol to exert potent anti-inflammatory and immunosuppressive actions. It is indicated for a wide range of conditions responsive to corticosteroid therapy, including inflammatory disorders, autoimmune diseases, severe allergic reactions, and respiratory conditions such as asthma. Lucky Core Industries, a diversified Pakistani conglomerate, provides Deltacortil as part of its pharmaceutical portfolio, which includes both toll-manufactured and imported products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Deltacortil.